Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Mar 12, 2007

Protherics Receives over $19M Milestone from AstraZeneca

  • Protherics reports that a £10-million milestone payment from AstraZeneca was triggered as a result of the successful scale-up of the CytoFab™ manufacturing process to a 600-L batch size.

    Upon receipt of this manufacturing-related milestone of over $19M, Protherics will have received a total of GBP26.3 million, or over $50.7 million, in milestone payments from AstraZeneca since the deal was signed in December 2005.

    Under the licensing agreement, Protherics may receive up to a further £161 million, or about $310 million, in milestone payments, in addition to a 20% royalty on global net product sales of CytoFab™.



Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »